Practical NeurologySignificant Differences in Therapy Discontinuation Rates Seen in Study of CBRP mAbs and Botox to Treat Migraine

Could improving CGRP mAb therapies be key to enhancing migraine management?

A recent retrospective cohort study has explored treatment persistence among migraine patients using specific calcitonin gene-related peptide (CGRP) monoclonal antibody (mAb) therapies or Botox, providing a fresh perspective on the efficacy of these treatments.

Key Points:

• The study used data from the IQVIA PharmMetrics Plus database to compare treatment persistence in migraine patients using specific CGRP mAb therapies or Botox.
• The specific CGRP mAb therapies examined were Aimovig, Ajovy, Emgality, and Vyepti.
• The probability of remaining on therapy following a 15-day gap was similar for patients taking either Vyepti or Botox.
• The discontinuation rate of subcutaneous CGRP mAbs was significantly higher than that of Vyepti based on 15-day, 30-day, and 60-day treatment gaps among patients with a history of prior CGRP mAb or Botox use.

Additional Points:

• Eligible patients for the study were adults (over 18 years) with migraine who had at least one prescription claim for one of the studied CGRP mAb treatments or Botox and had a minimum of 12 months of continuous medical and pharmacy coverage.
• A total of 66,567 patients with mean ages of 45-47 years and primarily females (86%-90%) were included in the study.
• A 15-day gap in therapy was considered as discontinuation.

Conclusion:

• CGRP mAb therapies, especially when subcutaneously administered, have a higher rate of discontinuation than Vyepti, suggesting a potential area of focus for improving migraine management.

Neurology Latest Posts

• Alcohol and the Brain Interact Through Immune Cells, New Research ShowsOctober 22, 2026
• The Genetic Landscape of Myotonic Dystrophy Type 1: Insights from Nearly One Million GenomesOctober 22, 2026
• Blood Levels of Key Protein May Help Predict MS ProgressionOctober 22, 2026
• Kappa Free Light Chains in the 2024 McDonald Criteria: What Neurologists Need to KnowOctober 22, 2026
• Prenatal COVID-19 Exposure and Childhood Neurologic RiskOctober 22, 2026

Did You Know?
As per a 2021 report by the World Health Organization, migraines are the third most prevalent illness in the world, affecting approximately 14% of the global population.